Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• Prostate-specific membrane antigen PET (PSMA PET) imaging is increasingly used for biochemically recurrent prostate cancer (BCR).
• It is recommended by major urological and oncological guidelines.
• This review focuses on recent evidence regarding PSMA PET in BCR management.

Purpose of the Study:

• To review the accuracy, management impact, and clinical benefit of PSMA PET in BCR.
• To discuss the role of PSMA PET in future clinical trials and routine practice.
• To assess its potential for improving patient outcomes.

Main Methods:

• Systematic reviews.
• Prospective trials.
• Large-scale retrospective studies.

Main Results:

• PSMA PET demonstrates superior detection rates and accuracy compared to standard imaging for BCR localization.
• Evidence establishes PSMA PET as a benchmark imaging modality.
• Significant impact on therapeutic and diagnostic management observed, with noted interpretation pitfalls.

Conclusions:

• PSMA PET is the imaging method of choice for BCR, offering high accuracy and detection rates.
• Management changes are common following PSMA PET scans.
• Demonstrating improved oncologic outcomes through clinical trials is the next crucial step.